Australian HealthTech Market: 2026 State of Play & Outlook to 2028

Nelson Advisors
1 hour ago
17 min read

Executive Summary

Australia's healthtech sector is exhibiting structural, not cyclical, growth in 2026. The digital health market, valued at USD $8.9 Billion in 2025, is forecast to reach USD $31.1 Billion by 2034 at a CAGR of 14.92%, underpinned by AI-led diagnostics, remote patient monitoring, aged care digitisation and a Federal Government committing billions to national digital health infrastructure.

Private capital fundraising hit AUD $416 Million across 11 ANZ healthtech deals in CY25, representing a 101% increase over CY24 value, while M&A volume reached its highest level since 2021. For international investors and M&A advisors, Australia is increasingly on the radar: ASX Healthcare is trading at multi-year lows while global healthcare PE deployment reached record levels globally, positioning the country for renewed offshore capital inflows.

Market Size & Growth

Australia's digital health market was valued at USD $8.9 Billion in 2025 and is on a trajectory to exceed USD $31.1 Billion by 2034, growing at a CAGR of 14.92%. The broader Healthcare IT sub-market sits at USD $11.4 Billion (2025), projected to hit USD $31.6 Billion by 2034 at a CAGR of 11.67%.

The telehealth sub-segment, which has normalised significantly since its COVID-era peak, reached USD $542 Million in 2025 and is forecast to grow at 18.16% CAGR to reach USD $2.56 Billion by 2034, driven by rural access imperatives and chronic disease management demands.

The ANZ listed healthtech sector had a total market cap of approximately AUD $15.7 Billion as of June 2026. The ASX-listed healthtech index is trading at roughly 25.9x revenue and 33.2x earnings, well off the highs of 2025 (when the index reached AUD $28.6 Billion), creating an attractive entry environment for acquirers and investors who take a long-term view.

Australia's MedTech market reached USD $8.9 Billion in 2025, and is projected to reach USD $14 Billion by 2034, driven by ageing demographics, IoT-integrated wearables, and rising chronic disease prevalence. The country's healthcare and social assistance sector now employs over 17% of the national workforce and is Australia's fastest-growing industry.

Leading Listed HealthTech Companies

Pro Medicus (ASX: PME)

Pro Medicus is Australia's most significant healthtech success story globally, a radiology imaging software provider whose SaaS-based Visage platform has become the de facto enterprise standard for major US hospital networks.

In HY 2026, the company delivered record revenue of AUD $124.8 Million, up 28.4% year-on-year, with underlying EBIT margins of 72.6% and profit after tax surging 230.9% to AUD $171.2 Million. Revenue increased across all key geographies: North America up 35.8% in FY25, Australia up 4.9% and Germany up 8.6%.

The company secured seven new contracts in HY 2026 totalling over AUD $280 Million at minimums, including a USD $170 Million University of Colorado Health deal, the second-largest in company history.

Pro Medicus remains debt-free with AUD $221.8 Million in cash and investments, and has grown earnings at a compound annual rate of 38.2% over recent years. With approximately 10% of the US total addressable market, significant runway remains.

4DMedical (ASX: 4DX)

Melbourne-based 4DMedical has been one of the ASX's standout healthcare performers, with shares up more than 1,100% over the year to June 2026. The company's CT:VQ™ received FDA 510(k) clearance in September 2025 as the world's first non-contrast ventilation-perfusion imaging solution, with CMS confirming reimbursement under Category III CPT codes.

In February 2026, 4DMedical secured US $100 Million+ in new institutional capital to accelerate US expansion and deepen integrations with Stanford, Cleveland Clinic, and UC San Diego Health. In May 2026, the company acquired Vienna based contextflow GmbH, entering Europe's respiratory and thoracic imaging market (estimated at USD $1.5–2 Billion) in a capital-efficient deal at AUD $1.86 Million upfront plus earn out.

4DMedical also signed a strategic distribution agreement with Philips to distribute CT:VQ across US and Canadian healthcare systems, and landed a GlaxoSmithKline deal in April 2026 for lung imaging analytics in drug development. Market cap as of June 2026: approximately AUD $2.8 Billion.

Cochlear (ASX: COH)

Cochlear remains one of Australia's most globally significant MedTech companies, with a market cap of approximately AUD $17.6 Billion. The company's hearing implant solutions continue to command high market penetration globally, with analyst consensus price targets of AUD $302.44 against a current price of AUD $268.51

Sonic Healthcare (ASX: SHL)

Australia's largest listed pathology provider, with a market cap of approximately AUD $11.5 Billion. Sonic is executing a selective digital transformation agenda, embedding diagnostic AI into its pathology networks and evaluating AI-assisted workflow tools from companies including Harrison.ai's pathology product.

ResMed (NYSE: RMD, ASX: RMD)

Though dual-listed and operationally centred in the US, ResMed's origins and significant R&D presence remain in Australia. The company leads globally in cloud-connected CPAP and respiratory care devices, and is increasingly an AI-driven digital therapeutics platform across 140 million patients.

Sigma Healthcare / Chemist Warehouse (ASX: SIG)

Sigma completed its transformative merger with Chemist Warehouse in early 2024, creating Australia's largest pharmacy retail and wholesale network with a market cap of approximately AUD $33.4 Billion. Sigma is expanding digital health capabilities across its Chemist Warehouse footprint, and has significant procurement leverage for digital health software and pharmacy automation.

Other Notable Listed Players

Nanosonics (ASX: NAN): Infection prevention and ultrasound probe reprocessing; market cap AUD $1.2 Billion, growing at 19.7% with analyst targets at AUD $4.63.

Integral Diagnostics (ASX: IDX): Radiology imaging network; market cap AUD $972.8 Million, growing at 31.3%.

Alcidion (ASX: ALC): Hospital and health system AI-driven clinical intelligence software; market cap AUD $504 Million.

Beamtree (ASX: BMT): Clinical intelligence and coding software for hospitals and payers

PYC Therapeutics (ASX: PYC): RNA-based therapeutics targeting rare diseases

Privately-Held Companies to Watch

Harrison.ai (Sydney)

Australia's flagship clinical AI company builds AI-powered diagnostic support tools for radiology and pathology. Its Annalise AI product detects up to 124 findings on chest X-rays and 130 findings on non-contrast head CTs.

In February 2025, Harrison.ai closed a USD $112 million (AUD $179 million) Series C, its largest round to date, co-led by Aware Super, ECP Asset Management, and Horizons Ventures, with the Australian Government's National Reconstruction Fund Corporation (NRFC) contributing AUD $32 Million in equity, its first investment in the medical science sector.

Total capital raised now stands at USD $240 Million. The NRFC investment was explicitly designed to anchor the company in Australia and prevent an offshore acquisition. The company operates in over 1,000 healthcare facilities worldwide, including the UK's National Health Service, and is commercialising into Southeast Asia via a January 2026 growth round of AUD $160 Million (Series C extension). Harrison.ai also established Franklin.ai, a pathology AI product, with a prostate biopsy analysis product entering the market in 2025.

Heidi Health (Melbourne)

Heidi is an ambient AI company providing AI-powered clinical documentation, its system transcribes consultations, auto-generates clinical notes, referral letters, and patient summaries directly into EHR systems.

The company closed a US$65 Million (AUD $98.4 Million) Series B in October 2025, led by Point72 Private Investments with backing from Blackbird and Headline. Heidi is now valued near US$465 Million and has over 1.5 Million sessions weekly across more than 50 countries, with expansion capital earmarked for the US, UK and Canada.

Heidi exemplifies the administrative AI automation trend, targeting the enormous cost burden of clinical documentation in healthcare systems globally.

Synchron (Melbourne / NYC)

An endovascular brain-computer interface (BCI) company that has raised USD $325 Million across four rounds. Founded by Australian neuroscientist Thomas Oxley, Synchron's stent-based BCI, the Stentrode, is implanted via the jugular vein rather than open brain surgery, giving it a significant safety advantage over competitors.

The company is conducting pivotal trials in the US and Australia, with clinical data demonstrating ALS patients controlling digital devices with thought alone. Synchron is considered a strong IPO or M&A candidate in the 2026–2027 window.

Everlab (Melbourne)

Preventive health clinic provider using full-body MRI scanning and AI-driven health intelligence for early disease detection in asymptomatic patients. Raised a US$10 Million seed round in July 2025 led by Left Lane Capital, with the capital earmarked for international expansion into Europe, the US, and APAC in 2026. Everlab is positioning at the intersection of longevity medicine, preventive care, and consumer health, a fast-growing vertical globally.

Kismet Healthcare (Melbourne)

An NDIS and disability services platform that raised a AUD $12.5 Million round led by Acorn Capital (Square Peg's most recent HealthTech investment). Kismet targets Australia's underserved disability care coordination market, which is being digitised rapidly as a result of the National Disability Insurance Scheme reform agenda.

Vaxxas (Brisbane)

Biotech company commercialising a patch-based vaccine delivery technology that enhances vaccine immune response while eliminating the need for needles and cold-chain logistics. Raised USD $82.8 Million across two rounds. The company holds strategic significance for pandemic preparedness and developing-market vaccine access.

Annalise.ai (Sydney)

Clinical AI focused on chest X-ray analysis, complementary to Harrison.ai but with a distinct product roadmap and clinical evidence base. Actively raising in 2025–2026.

Venture Capital Investment Landscape

Volume & Trajectory

Private healthtech fundraising in ANZ reached AUD $416 Million across 11 deals in CY25, the highest value since CY21's AUD $586 Million boom year and preliminary data suggests 2026 is on track to exceed this, with approximately AUD $620 Million raised in the first two months of 2026 alone.

AI-powered diagnostics and remote patient monitoring together accounted for 58% of capital raised in early 2026, up from 34% in the same period a year prior. Telehealth, which dominated in 2020–2022, has dropped to single-digit percentage shares as consolidation around established players has occurred.

Fund Structure Shifts

The broader Australian VC fund formation market is undergoing a structural shift. Generalist mega-funds (AUD $500 Million+) have stalled, no Australian-headquartered VC closed above AUD $500 Million in 2025. Instead, specialist vehicles of AUD $50–$150 Million with sector-experienced GPs are closing in 6–9 months and commanding strong LP commitment.

Healthtech and life sciences specialist funds represent one of the fastest-closing categories. LP bases include Australian superannuation funds (Aware Super notably co-led Harrison.ai's Series C), family offices, and increasingly offshore endowments.

Key Active VC Investors

Investor	Stage Focus	Notable ANZ HealthTech Portfolio
Blackbird Ventures	Seed to growth	Heidi Health, Harrison.ai
Square Peg Capital	Growth	Kismet Healthcare, NexusMD.ai
AirTree Ventures	Seed to Series B	updoc, Access Telehealth
Bailador Technology Investments	Growth (listed fund)	Exited InstantScripts (5x MoM)[^3]
Left Lane Capital	Growth (global)	Everlab
Point72 Private Investments	Growth (global)	Heidi Health
Horizons Ventures	Growth (global)	Harrison.ai
Aware Super	Growth / co-investment	Harrison.ai
National Reconstruction Fund Corp.	Government equity	Harrison.ai

Private Equity Acquisitions

Deal Volume & Character

ANZ healthtech M&A reached AUD $617 million across 11 deals in CY25, the highest volume since CY21. The market remains characterised by fragmentation: many niche, sub-scale providers with mission-critical software, creating durable acquisition logic for financial sponsors and strategic buyers.

The majority of M&A activity has focused on administrative and workflow software (bookings, practice management, pharmacy, aged care, EHR), reflecting the maturity and scale of these segments relative to clinical AI, which is still earlier in commercial cycle.

Landmark 2025–2026 Transactions

Quadrant Private Equity / Carlisle Health (August 2025)

Quadrant PE, one of Australia's largest PE firms at AUD $10 Billion+ AUM, acquired Carlisle Health at a AUD 200 Million enterprise value. Carlisle operates a 27-clinic diagnostic imaging network across NSW and Queensland, with over 500 staff and 70+ radiologists.

The deal represents a classic PE consolidation play in Australia's fragmented radiology market, with Quadrant bringing an M&A acquisition pipeline strategy, GE HealthCare equipment partnership and PET/nuclear medicine expansion. Debt was provided by Metrics Credit Partners and QIC.

Wesfarmers Health (AKA "CW Health") / API acquisition and platform build

Wesfarmers Health (formed via the AUD $1.03 Billion API acquisition in March 2022) has built Australia's most integrated consumer health platform through subsequent bolt-on acquisitions: telehealth provider InstantScripts (~AUD $135 Million EV), SiSU Health (preventive screening kiosks), SILK Laser Clinics (~AUD 180 Million EV), and Clear Skincare.

TA Associates / Clanwilliam Group (November 2025)

TA Associates completed approximately a USD 450 Million acquisition of Clanwilliam Group, an Irish-based multinational EHR technology provider with significant ANZ operations including HealthLink (Australasia's leading secure health messaging network connecting 15,000+ medical organisations) and MedicalDirector-lineage assets. The deal included a USD $115 Million committed M&A facility and positions Clanwilliam for further ANZ acquisitions.

Major ANZ HealthTech M&A by Target Segment (2025–2026)

Date	Segment	Approx. EV
Feb-26	Telehealth	AUD 1.6 billion
Dec-25	GP booking platform	AUD 250 million+
Jun-25	Aged and disability care software	AUD 300 million+
Aug-25	Carlisle Health (diagnostic imaging)	AUD 200 million
May-25	Virtual pharmacist	AUD 42.4 million
Dec-24	Healthcare software solutions	AUD 182.1 million
Dec-23	Breast health (Volpara)	AUD 285.5 million

The February 2026 AUD $1.6 Billion telehealth acquisition is the largest disclosed ANZ healthtech M&A transaction and signals the sector has now matured to attract mega-PE and strategic deal sizes consistent with US and European comparisons.

Strategic Platform Builders to Watch

Telstra Health — a leading enterprise digital healthcare software provider serving 1,200+ healthcare organisations across hospitals, aged care, pharmacy, and government. Telstra is rumoured to be evaluating strategic options for this division, making it one of the most significant potential divestiture opportunities in the ANZ healthtech market. Any transaction could value Telstra Health north of AUD $1 Billion given its NHS UK presence and government contract base.

Magentus — formed in May 2023 through PE-backed consolidation of Citadel Health (oncology / pathology / radiology software), Genie Solutions (specialist practice management), and Wellbeing Software (UK). Acquired Labflow Pty Ltd (pathology laboratory software) in December 2025. Magentus is building the leading ANZ specialist clinical software platform, operating across Australia and the UK.

Government Initiatives & Funding

Federal Budget 2026: Digital Health Priority

The 2026 Australian Federal Budget marked the most substantial government commitment to digital health infrastructure in the country's history.

Key commitments include:

AUD $598.3 million over two years to enhance My Health Record, linked to the Modernising My Health Record (Sharing by Default) Act 2025, which expands default data-sharing arrangements

AUD $745.1 million over four years to strengthen Medicare digital system capability and integration

AUD $358.5 million over five years for a new NDIS digital enrolment and payment system

AUD $259.9 million in 2026–27 for aged care ICT sustainment and digital infrastructure uplift

AUD $210.6 million over eight years to fast-track national digital health infrastructure under the National Health Reform Agreement

AUD $99.5 million over five years for a National Digital Child Health Record within My Health Record

AUD $79.2 million over three years to states and territories for public hospital digital health reform implementation

AUD $13.3 million over two years for Sparked, a national FHIR accelerator to strengthen interoperability and consistency across the healthcare system

AUD $71 million over three years for Precision Oncology Screening to match cancer patients with genomic-based clinical trials

Medical Research Future Fund is expected to reach AUD $1 Billion per year by 2030–31

National Reconstruction Fund (NRF)

The NRFC has made medical science one of its seven priority investment areas, deploying its first equity investment (AUD $32 Million into Harrison.ai in January 2025) to anchor AI diagnostics capability in Australia and prevent offshore acquisition of strategic IP.

The NRFC's AUD $15 Billion mandate spans direct loans, equity investment, and loan guarantees, and represents a significant non-dilutive or co-investment source for Australian healthtech companies scaling globally.

Australian Digital Health Agency (ADHA)

The ADHA launched its Health Connect Australia Strategy, Architecture and Roadmap in 2025, setting out a phased national health information exchange program from 2025 to 2030+. The strategy is structured in four phases: Foundations (2025–2026), Sharing (2025–2028), Discovery (2027–2029) and Enhancement (2027–2030+). The programme prioritises interoperability, consumer-centric health data access, and a national provider directory.

The ADHA also received a AUD $33 Million contract from the Australian Digital Health Agency to upgrade the My Health Record system, awarded to Telstra Health. The Australian National Healthcare Interoperability Plan has now completed 75% of its planned actions, with the remaining 11 items due by July 2028.

Health Workforce Investment

The 2025–26 Federal Budget committed AUD $662.6 Million to health workforce development, including AUD 265.2 million to support GP and rural generalist training, with 1,300 new doctors entering GP training over four years from 2026.

By 2028, the government aims to fund over 2,000 GP trainees annually. This creates downstream demand for digital tools across primary care workflows, telehealth infrastructure, and clinical decision support AI.

Predictions: Key Trends for 2026–2028

1. Clinical AI Shifts from Pilot to Production

Australian hospitals are moving from AI pilots to full production deployments across radiology, pathology, and clinical documentation. Harrison.ai is expanding from approximately 1,000 facilities to a global scale across Southeast Asia and EMEA. Heidi Health's 1.5 Million weekly sessions in over 50 countries is a bellwether for ambient AI documentation becoming standard care infrastructure globally within two years.

2. Remote Patient Monitoring (RPM) Emerges as a Major Sub-Sector

RPM attracted AUD $180 Million across five ANZ deals in early 2026. The largest single deal was Vitalic Health's AUD$ 85 Million Series B for its chronic disease monitoring platform integrating wearable sensors with clinical decision-support. With Australia's ageing population, the case for hospital-at-home and chronic disease management via connected devices is structurally compelling.

3. Aged Care Digitisation Continues as a Dominant M&A Theme

Australia's aged care sector is in the midst of mandatory quality reforms following the Royal Commission into Aged Care. Software providers automating compliance, workforce management, care documentation, and resident engagement are attracting significant PE and strategic interest. CY25 saw at least three aged care software acquisitions, each above AUD $300 Million implied value.

4. Interoperability Becomes a Market Threshold, Not a Differentiator

The 2025 Modernising My Health Record (Sharing by Default) Act combined with the ADHA's Health Connect Australia strategy means FHIR-compliant interoperability will shift from a competitive advantage to a compliance minimum. This will accelerate replacement of legacy clinical systems and create significant upgrade cycles benefiting modern EHR and practice management vendors.

5. IPO Window Opens — Selectively

The ASX IPO window for healthtech is showing signs of recovery. I-Med Radiology is being prepared for a circa AUD $3 Billion listing, which would be one of the largest ASX healthcare IPOs in recent history. Synchron is also considered a strong IPO or private M&A candidate.

However, domestic IPOs face structural headwinds from limited specialist healthcare funds on the ASX and a shortage of natural lead investors, many companies are increasingly considering strategic investments from US-listed corporates offering technology validation at better valuations.

6. M&A Multiples: Compression Across Most Segments, Premium for Proven AI

ANZ healthtech M&A multiples have softened from peak 2021–2022 levels. Workflow and administrative software is trading at 1.7x–8.1x revenue depending on scale and growth profile. However, clinical AI platforms with proven clinical validation, reimbursement coverage, and global commercial traction (such as Pro Medicus or 4DMedical) command significant premiums, and the disparity between premium AI assets and commodity software will widen over the next two years.

Headwinds

1. Cybersecurity Threats

The Australian healthcare sector ranks as the highest-breached sector by the Office of the Australian Information Commissioner (OAIC). Healthcare organisations remain prime targets for ransomware and phishing attacks. The ADHA has published new My Health Records Rules 2026 requiring mandatory written security and access policies for all connected providers.

A major breach affecting a national platform or large hospital network remains a tail risk with potential to damage public trust and delay the digital health agenda significantly.

2. TGA Regulatory Complexity for AI-Enabled Devices

The TGA published updated guidance in February 2026 clarifying that AI-enabled software intended for diagnosis, monitoring, or treatment must be included in the Australian Register of Therapeutic Goods (ARTG) before supply. Synthetic data cannot replace clinical evidence in regulatory submissions.

For companies scaling AI diagnostics, this increases regulatory burden and extends commercialisation timelines — particularly challenging for small, well-funded startups managing multiple international regulatory pathways simultaneously.

3. Interoperability Fragmentation

Despite government investment, Australia's health system remains fragmented across hundreds of incompatible legacy systems at state, federal, hospital, and clinic level. The ADHA's 75% completion rate on the National Healthcare Interoperability Plan is encouraging, but the remaining 11 actions are the most complex. The ongoing absence of real-time, bidirectional data exchange between primary, secondary, and tertiary care remains a constraint on the value of AI diagnostic tools and remote monitoring platforms.

4. Healthcare Workforce Shortages

Australia faces a structural clinician shortage, the primary catalyst for the government's AUD 662 million workforce investment. Paradoxically, workforce shortages both drive demand for AI and digital health solutions (clinical workload automation, telehealth access) and constrain clinical validation and implementation timelines. Rural and remote health inequality remains a persistent challenge, with digital infrastructure and connectivity gaps in regions where technology could have the greatest impact.

5. Capital Market Constraints for Small-Cap Healthtech

While late-stage capital is abundant, early-stage and seed funding fell 51% in 2025. ASX healthcare is at multi-year valuation lows, limiting the ability of earlier-stage companies to IPO at fair values. Secondary raises have consistently priced at 10–15% discounts to last close. The limited pool of domestic specialist healthcare fund managers means offshore capital access — with its attendant complexity, dilution risk, and geopolitical considerations — is increasingly necessary for companies seeking AUD 100 million+ rounds.

6. Telehealth Regulatory Uncertainty

Australia's largest telehealth platform Eucalyptus has publicly called for stronger national safety and quality standards for online telehealth providers, noting that current regulation is insufficient. RACGP and other medical bodies have raised concerns about clinical governance in direct-to-consumer telehealth models. Regulatory tightening in telehealth — which is likely in the 2026–2027 period — could disadvantage pure-play telehealth providers and favour integrated models combining virtual and in-person care.

Tailwinds

1. Ageing Population & Chronic Disease Burden

Australia's demographic trajectory is a durable demand driver. Rising prevalence of chronic conditions including diabetes, COPD, and cardiovascular disease creates structural demand for remote monitoring, diagnostic AI, and preventive care platforms. The aged care digitisation wave, accelerated by Royal Commission reforms, is generating substantial software procurement across 2,700+ residential aged care providers.

2. Government as Anchor Customer and Investor

The 2026 Federal Budget's multi-billion dollar digital health commitment, combined with the NRFC's strategic equity investments, positions the government as both a paying customer (via Medicare system upgrades, My Health Record enhancement, NDIS platform development) and a co-investor willing to anchor healthtech companies in Australia. This reduces commercial risk for scale-up companies and creates clear implementation pathways for interoperability and data platform providers.

3. Clinical AI Reimbursement Momentum

4DMedical's CMS Category III CPT reimbursement for CT:VQ in the US is an important proof point that AI-driven imaging tools can achieve reimbursement recognition in major markets. As more Australian AI diagnostic tools progress through FDA and TGA regulatory pathways, reimbursement coverage will expand, converting clinical adoption into sustainable commercial models.

4. Weak Australian Dollar Creating Offshore Acquisition Interest

A weaker Australian dollar has increased international acquirer appetite, with US-listed corporates and global PE funds finding Australian healthtech assets attractively priced relative to US equivalents. Keysight Technologies (NYSE: KEYS) backed EMVision twice across 2024–2025 and Lantheus Holdings (NASDAQ: LNTH) backed RAD's theranostics platform twice, establishing a pattern of US strategic investors using Australian assets for technology validation and optionality at a cost below comparable US targets.

5. Specialist VC Fund Formation

The shift toward AUD $50–150 Million specialist healthtech VC vehicles is creating a more sustainable capital ecosystem for the sector. These sector-focused funds bring domain expertise to due diligence, reduce funding gaps for genuinely innovative healthcare startups, and build ecosystem relationships with hospital procurement teams, government agencies, and global strategic buyers.

6. Superannuation as Patient Capital

Australia's approximately AUD $4 Trillion superannuation system is increasingly allocating to private markets, including direct co-investment alongside PE and VC in healthtech. Aware Super's participation in Harrison.ai's Series C exemplifies how superannuation funds are moving beyond passive public markets to become active partners in Australia's most strategically important technology companies.

7. Global Expansion Opportunities

Australian healthtech companies are increasingly globalising from Australia. Harrison.ai, Pro Medicus, Heidi Health, 4DMedical, and Everlab are all executing international expansion strategies targeting the US, UK, EU, and Southeast Asian markets. The NHS in the UK represents a particularly important reference customer — Pro Medicus, Harrison.ai and Heidi Health all have NHS deployments, providing clinical validation evidence that accelerates adoption in other health systems.

M&A Valuation Benchmarks

Segment	EV/LTM Revenue	EV/EBITDA	Notable Comps
Telehealth (at scale)	5.0x–7.0x	n/a	Feb-26 AUD 1.6bn deal
GP/booking platform	4.0x–6.0x	n/a	Dec-25 AUD 250m+ deal
Aged care software	n/a (revenue quality)	n/a	Jun-25 AUD 300m+ deal
Breast health AI (Volpara)	8.1x	n/m	Dec-23 AUD 285.5m
Virtual pharmacist	1.7x	10.1x	May-25 AUD 42.4m
Practice management	n/a	n/a	Varies by ARR scale
Clinical AI (premium)	15x–25x+ ARR	n/a	Harrison.ai, Heidi implied comps

Strategic Implications for International Investors

The Australian healthtech market is at an inflection point, large enough to produce genuinely global software businesses (Pro Medicus, 4DMedical, Harrison.ai), early enough in AI-driven healthcare that the most interesting clinical AI assets have not yet been acquired, and attractively valued relative to comparable US companies given the currency discount and ASX valuation compression.

The most actionable segments for international strategic buyers and PE in 2026–2028 are:

(1) clinical AI diagnostics with demonstrated hospital adoption and international expansion;

(2) administrative AI automation (clinical documentation, revenue cycle management);

(3) aged care and disability care software (structurally necessary, regulatory-driven demand);

(4) practice management consolidation platforms with recurring ARR across GP, specialist, and allied health; and

(5) remote patient monitoring with integration into chronic disease management pathways.

The Federal Government's explicit strategy to retain strategic healthtech IP in Australia (as demonstrated by the NRFC's Harrison.ai investment) means international acquirers must consider sovereign interest considerations in early engagement, a factor that favours European and UK strategic buyers (viewed as aligned partners) over US acquirers in regulated AI diagnostic segments.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech